TY - JOUR
TI - Cardiac and renal complications of carfilzomib in patients with multiple myeloma
AU - Dimopoulos, M.A.
AU - Roussou, M.
AU - Gavriatopoulou, M.
AU - Psimenou, E.
AU - Ziogas, D.
AU - Eleutherakis-Papaiakovou, E.
AU - Fotiou, D.
AU - Migkou, M.
AU - Kanellias, N.
AU - Panagiotidis, I.
AU - Ntalianis, A.
AU - Papadopoulou, E.
AU - Stamatelopoulos, K.
AU - Manios, E.
AU - Pamboukas, C.
AU - Kontogiannis, S.
AU - Terpos, E.
AU - Kastritis, E.
JO - Blood advances
PY - 2017
VL - 1
TODO - 7
SP - 449-454
PB - American Society of Hematology
SN - null
TODO - 10.1182/bloodadvances.2016003269
TODO - null
TODO - Clinical trials with carfilzomib have indicated a low but reproducible incidence of cardiovascular and renal toxicities. Among 60 consecutive myeloma patients treated with carfilzomib-based regimens who were thoroughly evaluated for cardiovascular risk factors, 12% (95% confidence interval, 3.8%-20%) experienced a reversible reduction of left ventricular ejection fraction (LVEF) by $20%, an objective measure of cardiac dysfunction. The incidence of LVEF reduction was 5% at 3 months, 8% at 6 months, 10% at 12 months, and 12% at 15 months, whereas the respective carfilzomib discontinuation rate unrelated to toxicity was 17%, 35%, 41%, and 49%. The presence of any previously known cardiovascular disease was associated with an increased incidence of cardiac events (23.5% vs 7%; P 5 .07), but there was no association with the dose of carfilzomib or the duration of infusion. Re-treatment with carfilzomib at lower doses was possible. Carfilzomib was commonly associated with a transient reduction of estimated glomerular filtration rate (eGFR) but also improved renal function in 55% of patients with baseline eGFR,60 mL/min/1.73 m2. Further investigation is needed to elucidate the underlying mechanisms of carfilzomib-related cardiorenal toxicity. © 2017 by The American Society of Hematology
ER -